Loading
A phase 2 trial of Adebrelimab, Carboplatin, Cisplatin and SHR-8068 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors is a phase 2 interventional study registered as NCT07028281 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 120 participants planned, started 2025-07-08 and due to reach its primary completion in 2028-12. Interventions recorded: SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/